Welcome back to the journal review. This is our walkthrough of the Journal of the American Academy of Dermatology for November twenty twenty-six, and we've got four pieces on deck today — a surgical pearl on OR ergonomics, a two-part continuing medical education series on mastocytosis, and a letter to the editor on artificial intelligence in evidence synthesis. Let's get into it. First up is a surgical pearl, so think of this as a quick practical tip rather than a full study — no methods, no control group, just a clever ergonomic fix the authors wanted to share. The setup is one every Mohs surgeon knows in their bones, literally: we spend our careers in prolonged neck flexion, peering down at a surgical field, and the ergonomics literature on surgeons generally — and dermatologic surgeons specifically — has been flagging this for years. The authors cite a survey showing high rates of musculoskeletal pain in the neck, upper and lower back, and shoulders among dermatologic surgeons, alongside a real gap in ergonomic training and tool adoption in our specialty. We've got loupes, adjustable stools, better lighting — but nothing that specifically unloads the cervical spine during the actual act of looking down at a wound. Their solution borrows from an unlikely place — those novelty "lazy glasses" people use to watch television while lying flat in bed. The optical trick is a ninety-degree reflecting prism that bends the sightline so you can view something below you while your head stays level. The authors took a lightweight clip-on version of this prism, something in the thirty-to-forty gram range, with a spring-loaded clip that attaches to the bridge of standard glasses or surgical goggles, and wore it intraoperatively. The physics is simple: the prism redirects the incoming image so the surgeon can visualize the anteroinferior surgical field — the Mohs stage, the suture line — while keeping the head in a neutral, forward-facing position instead of flexed downward. There's an accompanying video demonstrating the intraoperative view. There's no outcomes data here, no measured reduction in cervical strain or EMG studies of neck musculature — this is presented purely as a proof-of-concept ergonomic solution, so the takeaway is practical curiosity rather than practice-changing evidence. If you're someone who finishes a long Mohs day with a stiff neck, this is a low-cost, low-friction thing you could trial yourself — it clips onto gear you already wear. It's not going to replace proper loupe angulation or monitor height optimization, but as an adjunct for those moments of sustained downward gaze during layered closures or tissue processing review, it's a reasonable low-risk experiment. File it under "interesting tool worth trying," not "guideline-changing." Now let's move into the bigger lift of this issue — a two-part CME series on mastocytosis. This is a review article, so there's no methods or results section to walk through in the research sense; instead it's a synthesis of current understanding, organized to build from basic biology up through classification in part one, and then diagnosis and management in part two. I'll take you through both parts together since they're really one continuous narrative. Part one starts with mast cell biology itself, which is worth pausing on because it reframes mastocytosis correctly as a disease of a cell type we usually think about only in the context of urticaria or anaphylaxis. Mast cells are tissue-resident sentinels concentrated at host-environment interfaces — skin very much included — and their development depends on stem cell factor signaling through the KIT receptor. They're activated through multiple pathways, classically IgE cross-linking via the high-affinity IgE receptor, but also through complement, IgG, and pattern recognition receptors, and they're implicated well beyond allergy — in bullous pemphigoid, atopic dermatitis, acne, inflammatory bowel disease, and even tumor microenvironments. Mastocytosis itself is a clonal neoplasm of mast cells, and the molecular story is dominated by KIT. Gain-of-function KIT mutations are found in the vast majority of adult systemic mastocytosis cases, with the KIT D816V mutation as the single most common driver — present in the large majority of adult systemic disease, but a much smaller minority of pediatric systemic and adult cutaneous cases. There's a second, less common mutation, KIT Del419, that's more of a pediatric phenomenon. The practical point for us is that nearly all of these mutations are somatic, not germline, so this isn't something you're routinely counseling families about as an inherited risk, outside rare familial case reports. On epidemiology, the disease has a clean bimodal story. Pediatric mastocytosis typically shows up before age two, is overwhelmingly cutaneous rather than systemic, and the biology is reassuring — most cases resolve by adolescence, and persistence into adulthood is the real red flag for occult systemic disease. Adult-onset disease is almost the mirror image: onset is typically in the mid-to-late fifties, and here's the number that should change how you think about every adult patient with classic cutaneous lesions — over ninety-five percent of adults with the classic skin findings already have systemic involvement. That's a striking figure, and it means for us as dermatologists, seeing typical maculopapular lesions in an adult is functionally a trigger for systemic workup, not a reassuring isolated skin diagnosis the way it often is in kids. Classification follows World Health Organization criteria, revised most recently in twenty twenty-three, with a competing but overlapping International Consensus Classification scheme. The big divide is cutaneous mastocytosis versus systemic mastocytosis, and systemic disease is further split into indolent, smoldering, aggressive, systemic mastocytosis with an associated hematologic neoplasm, and mast cell leukemia — plus bone marrow mastocytosis as its own entity. The prognostic spread across these subtypes is enormous, ranging from essentially normal life expectancy in indolent disease to rapidly fatal courses in leukemic transformation, which is exactly why getting the subtype right matters so much clinically. Part two picks up with the diagnostic and management workup, and this is really where the dermatologist's role gets concrete. The authors are explicit that skin findings are often the entry point into the whole diagnostic cascade, so recognizing the morphology matters. In pediatric patients, you're looking for either diffuse cutaneous mastocytosis or the maculopapular form, sometimes with solitary mastocytomas — and here's a genuinely practical pearl — don't attempt to elicit Darier sign in a suspected mastocytoma, because vigorous stroking can provoke flushing and systemic hypotension. In adults, maculopapular cutaneous mastocytosis predominates, typically starting on the trunk, sparing the face and hands, and can be triggered into pruritus by heat, friction, alcohol, or spicy food even when asymptomatic at baseline. One nuance worth remembering: as systemic disease advances, cutaneous lesions can actually regress, so absence of classic skin findings doesn't rule out advanced systemic mastocytosis — only about half of patients with advanced disease still show the typical skin lesions, compared to nearly all patients with indolent disease. On biopsy, a skin specimen showing fifteen or more mast cells per high-power field satisfies a minor diagnostic criterion for systemic disease, and density in lesional skin typically runs four to eight times normal. Immunohistochemistry panels — tryptase, CD117, and the aberrant markers CD25 and CD2 — support the diagnosis, and CD25 positivity is particularly useful in advanced disease. But the real diagnostic anchor for systemic disease is bone marrow biopsy, needed in over ninety percent of systemic mastocytosis cases to confirm multifocal dense mast cell aggregates, assess fibrosis, and rule out an associated hematologic neoplasm. Practically, that means any adult with suspicious cutaneous findings or an elevated serum tryptase should be routed toward hematology for marrow sampling rather than managed on skin findings alone. The management section, which I'll note is covered in the back half of part two beyond what's excerpted here, emphasizes a genuinely multidisciplinary model — dermatology for cutaneous disease and initial recognition, allergy for mediator-related symptom control, and hematology-oncology for systemic and advanced disease — with a nod toward the emerging promise of KIT D816V-targeted inhibitors for both symptomatic indolent and advanced systemic mastocytosis, representing a real shift from purely symptomatic management toward disease-modifying therapy in appropriate patients. Since this is a review rather than original research, there's no statistical methodology to teach here, and no limitations section in the traditional sense — the value of this one is purely synthetic. For practice, the actionable points are: treat classic maculopapular lesions in an adult as a systemic workup trigger, remember that absent skin findings don't exclude advanced disease, avoid provoking Darier sign in suspected solitary mastocytomas, and know that serum tryptase and bone marrow biopsy — not skin biopsy alone — are what confirm or exclude systemic involvement. The targeted KIT inhibitor data is worth watching but sits more in the medical oncology and allergy lane than something that changes your Mohs or excisional practice directly. Last on the docket is a letter to the editor — a response from the JAAD editor, Dirk Elston, to a previous piece by Kahn and colleagues on artificial intelligence in evidence synthesis. This is a short opinion piece, so there's no data to walk through, just a position being staked out. The core argument is that while AI tools are increasingly tempting for synthesizing large bodies of literature, they cannot judge the validity of underlying data, the qualifications of authors, or the rigor of methodology — and critically, AI itself bears no accountability for errors it introduces. The letter flags specific failure modes we should all have on our radar: fabricated references, inadvertent plagiarism through unattributed appropriation of others' work, misattribution of data to the wrong source, and distortion of an original author's actual interpretation. There's also a practical privacy point — feeding manuscript data into public AI tools means that data can be retained, resold, or used to train future models, which has real implications if you're using these tools on unpublished research or patient-adjacent data. The author's personal practice, which he offers as a model, is to use AI for initial topic exploration but then independently verify everything through manual PubMed and Google Scholar searches — and he notes candidly that the AI-generated and manually-verified conclusions often don't align. The take-home message is squarely about accountability: if your name is on the manuscript, you own the search methodology, the validation of every reference, and the interpretation of the data, regardless of what tool helped you get there. For practical purposes, this isn't practice-changing in a clinical sense, but it is a useful editorial stance to internalize if you're involved in writing reviews, consensus statements, or even using AI tools to help draft patient materials — disclose the use, and verify, verify, verify before anything goes out under your name. That wraps up this episode. To summarize: a simple prism-based ergonomic trick worth trying if neck strain is part of your daily OR experience, a thorough two-part refresher on mastocytosis that sharpens exactly when a dermatologist's skin findings should trigger systemic workup, and an editorial reminder that AI is a research accelerant, not a substitute for your own verification and judgment. Thanks for listening, and I'll see you next month.